Interpreting the DIGIT-HF trial: Time for a new look at digitalis?

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Heart failure with reduced ejection fraction (HFrEF) remains a significant cause of morbidity and mortality.
• Guideline-directed medical therapy (GDMT) is the cornerstone of HFrEF management, but further therapeutic options are needed.
• Digitoxin, a cardiac glycoside, has been investigated for its potential benefits in heart failure.

Purpose of the Study:

• To evaluate the efficacy and safety of digitoxin when added to GDMT in patients with advanced HFrEF.
• To determine the impact of digitoxin on the composite endpoint of all-cause death or first hospitalization for worsening heart failure.

Main Methods:

• The DIGIT-HF trial was a randomized, placebo-controlled study.
• Patients with HFrEF received either digitoxin or placebo, in addition to their existing GDMT.
• The primary composite endpoint was assessed over a median follow-up of 36 months.

Main Results:

• Digitoxin demonstrated an 18% reduction in the composite endpoint of death from any cause or first hospitalization for worsening heart failure compared to placebo (hazard ratio 0.82; 95% CI 0.69-0.98).
• No statistically significant differences were observed in all-cause mortality, first hospitalization rates, or serious adverse events between the digitoxin and placebo groups.
• The median follow-up duration was 36 months.

Conclusions:

• Digitoxin, as an add-on therapy to GDMT, significantly reduces the risk of hospitalization for worsening heart failure or death in patients with HFrEF.
• Digitoxin appears to be a safe therapeutic option in this patient population, with no significant increase in adverse events.
• These findings suggest a potential role for digitoxin in the management of advanced chronic heart failure.